Broadpoint Downgrades MTS Medication (MPP) to Neutral
More News related to MPP
- Broadpoint Downgrades MTS Medication (MPP) to Neutral
- First Albany Starts MTS Medication Technologies (MPP) at Strong Buy
- MTS Medication Tech (MPP) Misses Q4 EPS by 1c, Guides for FY08
- Medication Technologies (MPP) Appoints Michael Conroy as CFO
More News related to Downgrades
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
- S&P Lowers BofA (BAC) Credit Outlook from Stable to Negative
Broadpoint downgrades MTS Medication (AMEX: MPP) from Strong Buy to Neutral, citing delay of revenue recognition from largest customer.
MTS Medication Technologies, Inc. (MTS) is a holding company that operates through the Company’s subsidiaries, MTS Packaging Systems, Inc. (MTSP), MTS Medication Technologies International, Ltd. (MTS Limited), BAF Printers, Ltd. (BAF) and Consilio GmbH (Consilio). [SM]
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
